Masimo Stock Declines Despite Solid Preliminary Q4 Revenues

Core Insights - Masimo Corporation (MASI) announced preliminary revenues for Q4 and full year 2025, showing strong performance despite a slight decline in share price [1][10] Group 1: Q4 2025 Preliminary Results - Estimated total revenues for Q4 2025 are $411 million, reflecting a 12% increase year over year on a reported basis and an 11% increase at constant exchange rates [2] - Adjusted earnings per share (EPS) for Q4 2025 are expected to exceed $1.54, surpassing the Zacks Consensus Estimate of $1.40 [2][10] - Shipments of non-invasive technology boards and instruments are projected to be 69 thousand for Q4 2025 [3][10] Group 2: Full-Year 2025 Preliminary Results - Total revenues for the full year 2025 are estimated at $1,523 million, a 9% increase from 2024, both on a reported basis and at constant exchange rates [4] - Adjusted EPS for the full year is expected to exceed $5.55, compared to the previous guidance range of $5.40 to $5.55, and above the Zacks Consensus Estimate of $5.41 [5] Group 3: Business Performance and Strategy - Management highlighted strong momentum in the core healthcare business, with revenue growth driven by solid demand and improved contracting activity [6] - The successful divestiture of Sound United allows Masimo to focus on healthcare operations, using proceeds to strengthen the balance sheet and return capital to shareholders [7] - Strategic initiatives, including expanding partnerships and adoption of advanced monitoring technologies, are contributing to durable demand and improved revenue visibility [8] Group 4: Market Performance - Despite near-term tariff-related challenges, Masimo's ability to expand operating margins and achieve robust earnings growth enhances confidence in the stock [9] - Shares of Masimo have decreased by 10.9% from September 28 to January 3, 2026, contrasting with the industry's 10.3% rise and the S&P 500's 4.1% gain [11]